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We read with interest the review by El-Hattab et al. about treatment options for mitochondrial disorders (MIDs) [1]. We have the following
comments and concerns.
Though the review discusses some of the possible interventions in MIDs, a number of treatment options has not been addressed. Concerning CNS
abnormalities, the option of antiepileptic drug (AED) therapy should be discussed, since many of the MIDs, particularly pediatric MIDs, present with
various types of epilepsy. Discussion of the AEDs is crucial since some of them are mitochondrion-toxic and should not be applied at all or at least not
as first-line therapy [2]. Particularly adult MIDs may go along with Parkinson's disease and respond favorably to anti-Parkinson medication or deep
brain stimulation. Dystonia is a frequent CNS abnormality in MIDs and requires botulinum toxin or deep brain stimulation. Concerning the ocular
abnormalities, cataract surgery and anti-glaucoma treatment should be mentioned. Endocrine abnormalities also include thyroid and parathyroid
dysfunction, hypocorticism, and hypogonadism and respond to adequate hormone substitution [3]. Cardiac involvement, particularly cardiomyo-
pathy with heart failure, responds to heart failure therapy and in case of ineffectivity, heart transplantation should be considered [4]. Nothing is
reported about the treatment of nephrolithiasis or renal insufficiency. Hematological problems may require transfusions or stimulation of precursor
cells. A frequent problem is muscular respiratory insufficiency requiring artificial ventilation. Concerning the additional drug therapy, carnitine
substitution in secondary carnitine-deficiency needs to be mentioned. Ketogenic diet can be beneficial in drug-resistant mitochondrial epilepsy [5].
Overall, there are more therapeutic options for MIDs available than discussed. Because of the multisystem nature of MIDs a multidisciplinary
approach including options for each of the affected organs should be chosen. A multidisciplinary approach is necessary since MIDs are multiorgan
disorders either already at onset of the clinical manifestations or later in the disease course.
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